论文部分内容阅读
目的 研究进展期大肠癌根治术后应用肿瘤浸润淋巴细胞 (TIL)及重组白细胞介素 2(rIL 2 )联合化疗的临床治疗效果。方法 将 84例DukesB及DukesC期大肠癌患者于大肠癌根治术后采用前瞻性随机分组的方法分为 2组 :一组 44例 ,术后使用自身TIL及rIL 2联合 5 氟脲嘧啶及丝裂霉素C治疗 ;另一组 40例 ,术后单纯采用相同方案的化疗。随访 3年。结果 TIL及rIL 2联合化疗组患者 3年内局部复发率为 8% (3/ 40 ) ,化疗组为 2 7% (10 / 37) (P <0 0 5 )。TIL及rIL 2联合化疗组3年内远处转移率为 13% (5 / 40 ) ,化疗组为 35 % (13/ 37) (P <0 0 5 )。TIL及rIL 2联合化疗组 3年生存率为 90 % (36 / 40 ) ,化疗组为 73% (2 7/ 37) (P >0 0 5 )。两组的毒性反应差异无显著性。结论 对于进展期大肠癌根治术后患者 ,使用自身TIL及rIL 2联合化疗能明显降低局部复发及远处转移率 ,能提高临床治疗效果。
Objective To study the clinical effect of combined application of tumor infiltrating lymphocytes (TIL) and recombinant interleukin 2 (rIL 2) in patients with advanced colorectal cancer after radical operation. Methods Eighty-four patients with DukesB and DukesC stage colorectal cancer were divided into two groups by prospective randomization after radical operation of colorectal cancer: 44 cases were treated with TIL and rIL 2 combined with 5-fluorouracil and mitosis In the other group, 40 patients were treated with chemotherapy of the same protocol. Followed up for 3 years. Results The local recurrence rate in TIL and rIL 2 combined chemotherapy group was 8% (3/40) in 3 years and 27.7% (10/37) in chemotherapy group (P <0.05). The distant metastasis rate was 13% (5/40) in the TIL and rIL 2 combined chemotherapy group within 3 years and 35% (13/37) in the chemotherapy group (P <0.05). The 3-year survival rate was 90% (36/40) in the combination of TIL and rIL 2 and 73% (27/37) in the chemotherapy group (P> 0.05). There was no significant difference in toxicity between the two groups. Conclusion For patients with advanced colorectal cancer after radical operation, the use of their own TIL and rIL 2 combined with chemotherapy can significantly reduce the local recurrence and distant metastasis rates, can improve the clinical effect.